Welcome to our dedicated page for Corvus Pharmaceuticals news (Ticker: $CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Corvus Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Corvus Pharmaceuticals's position in the market.
Rhea-AI Summary
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) announces the passing of Edith P. Mitchell, M.D., a valued member of the Board of Directors. Dr. Mitchell had a distinguished career in healthcare and oncology, serving in various positions at Thomas Jefferson University and making significant contributions to cancer care and research. The Company extends its condolences to her family, colleagues, and community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
-
Rhea-AI Summary
Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company (NASDAQ: CRVS), announced new interim data from its Phase 1/1b clinical trial of soquelitinib in patients with relapsed peripheral T cell lymphoma. The data confirmed durable anti-tumor activity and supported the advancement of soquelitinib into a Phase 3 registrational clinical trial. The results showed progression free survival, duration of response, and overall survival rates that exceed current standard of care therapies for patients with relapsed PTCL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
News
Rhea-AI Summary
CRVS: Corvus Pharmaceuticals Finalizes Protocol for Soquelitinib Phase 3 Clinical Trial in PTCL, New Data Accepted for ASH Annual Meeting, Positive Preclinical Data in Solid Tumors and Autoimmune Conditions
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
Rhea-AI Summary
Corvus Pharmaceuticals will present new interim data from its Phase 1/1b trial of soquelitinib in patients with relapsed peripheral T cell lymphoma (PTCL) at the 65th ASH Annual Meeting & Exposition. The presentation will take place on December 9, 2023, and will focus on the immune regulatory mechanism of the ITK inhibitor Soquelitinib in refractory T cell lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
-
Rhea-AI Summary
Corvus Pharmaceuticals, Inc. has published preclinical data demonstrating the potential of ITK inhibition as a novel approach to treat T cell-mediated inflammatory and immune diseases. The data showed that soquelitinib, an ITK inhibitor, was effective in six disease models and inhibited the production of Th2 and Th17 cells, targeting cytokines such as IL-4, IL-5, IL-13, and IL-17. Corvus is currently conducting clinical trials for soquelitinib in oncology indications and developing next-generation molecules for inflammatory and immune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
-
Rhea-AI Summary
Corvus Pharmaceuticals, Inc. will host a conference call and webcast on November 7, 2023, at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2023 financial results. The conference call can be accessed by dialing 1-877-407-0784 (toll-free domestic) or 1-201-689-8560 (international) or via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.42%
Tags
Rhea-AI Summary
Corvus Pharmaceuticals plans to initiate a Phase 3 clinical trial for soquelitinib in Q1 2024, following a positive meeting with the FDA. The trial will enroll 150 patients with relapsed peripheral T cell lymphoma. The Company anticipates potential benefits in addressing a wide range of indications beyond hematologic cancers. The news is expected to positively impact the stock price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.53%
Tags
-
News
Rhea-AI Summary
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS) reports positive clinical results for soquelitinib in treating various cancers, including T cell lymphomas and solid tumors. They also announced plans for potential Phase 3 trials and highlighted preclinical data supporting the immunotherapeutic potential of soquelitinib. Additionally, updates on partner-led programs and financial results for the second quarter were provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
-
Rhea-AI Summary
Corvus Pharmaceuticals, Inc. will host a conference call and webcast on August 8, 2023, at 4:30 pm ET to provide a business update and report second quarter 2023 financial results. The conference call can be accessed by dialing 1-855-327-6837 (toll-free domestic) or 1-631-891-4304 (international) or via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
Corvus Pharmaceuticals, Inc.
Nasdaq:CRVS
CRVS Rankings
CRVS Stock Data
135.11M
34.40M
3.89%
39.96%
2.85%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
BURLINGAME
About CRVS
corvus pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. with accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.